Journal
EMBO JOURNAL
Volume 28, Issue 17, Pages 2662-2676Publisher
WILEY
DOI: 10.1038/emboj.2009.205
Keywords
Alk5; follistatin; heparin; myostatin; TGF-beta
Categories
Funding
- NIHGM [R01 GM084186]
- AHA [0635097N]
- MDA [93887]
- Canadian Institutes of Health Research [MOP-89991]
- NIDDK, NIH, USA
- CIHR
Ask authors/readers for more resources
Myostatin is a member of the transforming growth factor-beta (TGF-beta) family and a strong negative regulator of muscle growth. Here, we present the crystal structure of myostatin in complex with the antagonist follistatin 288 (Fst288). We find that the prehelix region of myostatin very closely resembles that of TGF-beta class members and that this region alone can be swapped into activin A to confer signalling through the non-canonical type I receptor Alk5. Furthermore, the N-terminal domain of Fst288 undergoes conformational rearrangements to bind myostatin and likely acts as a site of specificity for the antagonist. In addition, a unique continuous electropositive surface is created when myostatin binds Fst288, which significantly increases the affinity for heparin. This translates into stronger interactions with the cell surface and enhanced myostatin degradation in the presence of either Fst288 or Fst315. Overall, we have identified several characteristics unique to myostatin that will be paramount to the rational design of myostatin inhibitors that could be used in the treatment of muscle-wasting disorders. The EMBO Journal (2009) 28, 2662-2676. doi: 10.1038/emboj.2009.205; Published online 30 July 2009 Subject Categories: signal transduction; structural biology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available